首页> 外文OA文献 >Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia final results of AML-13, a randomized phase-3 study

【2h】

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia final results of AML-13, a randomized phase-3 study

机译：AML-13（一项3期随机研究）最终结果在61岁及以上的急性髓细胞白血病患者中，在诱导化疗期间和/或之后使用糖基化重组人G-CSF（来诺格司亭）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Amadori S., Suciu S., Jehn U., Stasi R., Thomas X., Marie J.-P., Muus P., Lefrere F., Berneman Z., Fillet G., Denzlinger C., Willemze R., Leoni P., Leone G., Casini M., Ricciuti F., Vignetti M., Beeldens F., Mandelli F., De Witte T.;
展开▼
作者单位

展开▼
年度 2005
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. [J] . Pautas C, Merabet F, Thomas Journal of Clinical Oncology . 2010,第5期

机译：年龄在50至70岁的急性髓细胞性白血病患者中增强蒽环类药物剂量诱导和重组白介素2维持治疗的随机研究：ALFA-9801研究的结果。
2. Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia [J] . Jiayu Huang, Ming Hong, Yu Zhu, Leukemia and lymphoma . 2018,第11a12期

机译：Defitabine与G-CSF，低剂量的细胞甘油蛋白和Aclarubicin的组合是在55至69岁的患者中诱导治疗的标准剂量化疗，具有新诊断的急性髓性白血病
3. Gemtuzumab ozogamicin (Mylotarg|[reg]|) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups [J] . S Amadori, S Suciu, R Stasi, Leukemia . 2005,第10期

机译：Gemtuzumab ozogamicin（Mylotarg | [reg] |）作为单药治疗61岁及以上的急性髓性白血病的体弱患者：AML-15B的最终结果，欧洲癌症研究与治疗组织的第二阶段研究和Gruppo Italiano Malattie Ematologiche dell'Adulto白血病团体
4. A Metadata-Based Patient Register for Cooperative Clinical Research: A Case Study in Acute Myeloid Leukemia [C] . Anja S. FISCHER, Ulrich MANSMANN Medical Informatics in Europe Conference. . 2011

机译：基于元数据的合作临床研究患者注册：急性髓性白血病案例研究
5. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study [D] . Harada Yasuhiko, 原田靖彦 2019

机译：根据2017年日本成人白血病研究组（JALSG）AML201研究治疗的成人急性髓性白血病患者的遗传学预测，根据2017 ELN风险分层进行预后分析
6. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13 a randomized phase-3 study [O] . Sergio Amadori, Stefan Suciu, Ulrich Jehn, -1

机译：糖化重组人G-CSF（来诺格司亭）在61岁及以上急性髓性白血病患者中进行诱导化疗期间和/或之后的使用：AML-13的最终结果一项随机的3期研究
7. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia : final results of AML-13, a randomized phase-3 study [O] . Amadori, Sergio, Suciu, Stefan, Jehn, Ulrich, 2005

机译：糖化重组人G-CSF（来诺格司亭）在61岁及以上急性髓性白血病患者中进行诱导化疗期间和/或之后的使用：一项AML-3期随机研究的最终结果
8. Chemotherapy in a Transplantable Myeloid Leukemia in Brown Norway Rats: Studies on BNML as a Model for Human Acute Myeloid Leukemia [R] . Golly, L. P. 1980

机译：Brown Norway大鼠可移植骨髓性白血病的化疗：BNmL作为人类急性髓性白血病模型的研究

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia final results of AML-13, a randomized phase-3 study

著录项

相似文献

相关主题

期刊订阅